Drug
Ro-Actemra
Ro-Actemra is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_4
3
75%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
3(75.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Other(2)
Detailed Status
unknown2
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 43 (75.0%)
Trials by Status
completed125%
recruiting125%
unknown250%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_2
Personalized Therapies in Inflammatory Complex Disease
NCT03651518
unknownphase_4
Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity
NCT02466581
unknownphase_4
Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction
NCT01491815
completedphase_4
A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action
NCT01638715
Clinical Trials (4)
Showing 4 of 4 trials
NCT03651518Phase 2
Personalized Therapies in Inflammatory Complex Disease
NCT02466581Phase 4
Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity
NCT01491815Phase 4
Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction
NCT01638715Phase 4
A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4